TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 3659227
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of Ci and Di
Study: 24001154
Drug: cilostazol (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: cilostazol (100 mg) plus GBE (80 mg)
Study: 24001154
Drug: cilostazol (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: cilostazol (100 mg) plus placebo
Study: 20934771
Drug: Propofol sedation
Normalized name: Propofol
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Propofol sedation (70-100 mg/procedure)
Study: 20934771
Drug: Midazolam sedation
Normalized name: Midazolam
DrugBank: Midazolam (DB00683)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Midazolam sedation (3-6 mg/procedure)
Study: 19559158
Drug: Literature review
Approvals — FDA: no, EMA: no, PMDA: no
Description: Literature review on treatment options for osteoporosis in IBD; specific interventions not detailed.
Study: 15447896
Drug: Biscuit meal
Normalized name: bone meal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Biscuit meal (17 g SAG/100 g)
Study: 15447896
Drug: Flakes meal
Normalized name: bone meal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flakes meal (2 g SAG/100 g)
Study: 9647493
Drug: Enalapril (5‐10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enalapril (5‐10 mg/day)
Study: 9647493
Drug: Metoprolol (40‐120
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metoprolol (40‐120 mg/day)
Study: 8004883
Drug: 25 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 25 mg cinnarizine
Study: 8004883
Drug: 50 mg
Normalized name: talc 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg cinnarizine
Study: 2547664
Drug: Combination chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination chemotherapy prior to elective surgery
Study: 2547664
Drug: Chemotherapy and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy and radiotherapy (comparison group)
Study: 23125444
Drug: Ad26-EnvA vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ad26-EnvA vaccine (10(9) vp, 10(10) vp, 10(11) vp)
Study: 23125444
Drug: Ad26-EnvA vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ad26-EnvA vaccine (10(11) vp)
Study: 23125444
Drug: Ad26-EnvA vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ad26-EnvA vaccine (10(9), 10(10), 10(11) vp 3-dose and 10(10) and 5 × 10(10) vp 2-dose groups
Study: 16627377
Drug: Orlistat (Xenical)
Normalized name: Orlistat
DrugBank: Orlistat (DB01083)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Orlistat (Xenical) 120 mg 3 times daily
Study: 15545095
Drug: 1540-nm Er:glass
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1540-nm Er:glass laser treatment (5 treatments at 6-week intervals)
Study: 15545095
Drug: Maintenance treatments
Normalized name: Dental Resources Perio Maintenance Rinse
Approvals — FDA: no, EMA: no, PMDA: no
Description: Maintenance treatments (2 additional treatments at 14 and 20 months)
Study: 10770196
Drug: Drug therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug therapy (fenfluramine, 60 mg/day) with energy restriction (−700 Cal/day)
Study: 9340029
Drug: Epidural patient-controlled
Normalized name: epidermal growth factor
DrugBank: Nepidermin (DB14145)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epidural patient-controlled analgesia (PCEA) with bupivacaine 0.25% + sufentanil 2 micrograms/ml (bolus 0.05 ml/kg, lockout 10 min)
Study: 9340029
Drug: Intravenous patient-controlled
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous patient-controlled analgesia (PCA) with morphine (bolus 2 mg, lockout 10 min)
Study: 3979482
Drug: Intravenous naloxone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous naloxone (2 mg)
Study: 30045066
Drug: Cariprazine 1.0-2.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cariprazine 1.0-2.0 mg/day
Study: 30045066
Drug: Cariprazine 0.1-0.3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cariprazine 0.1-0.3 mg/day
Study: 16149361
Drug: Controlled-release oxycodone
Normalized name: oxycodone
DrugBank: Oxycodone (DB00497)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Controlled-release oxycodone (CR oxycodone)
Study: 9799882
Drug: Alpha tocopherol
Normalized name: alpha tocopherol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alpha tocopherol 50 mg per day
Study: 9799882
Drug: Beta carotene
Normalized name: Beta Carotene
DrugBank: Beta carotene (DB06755)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Beta carotene 20 mg per day
Study: 383099
Drug: Fluphenazine decanoate
Normalized name: Fluphenazine Decanoate
DrugBank: Fluphenazine (DB00623)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Fluphenazine decanoate treatment
Study: 24612734
Drug: Axaven(®) once
Normalized name: gabapentin
DrugBank: Gabapentin (DB00996)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Axaven(®) once a day for 8 months as adjunctive treatment with standard treatment (compression therapy and surgical correction of superficial venous incompetence)
Study: 24612734
Drug: Basic treatment
Normalized name: Basic Fuchsin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Basic treatment according to clinical conditions (control group)
Study: 25587162
Drug: Endotracheal liquid
Normalized name: ALCOHOL 80 mL in 100 mL ENDOTRACHEAL LIQUID [80% Alcohol Hand Sanitizer]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Endotracheal liquid bolus (ELB) albuterol
Study: 25587162
Drug: Metered-dose inhaler
Normalized name: Metered Dose Inhaler
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metered-dose inhaler (MDI) albuterol
Study: 16384948
Drug: Ruboxistaurin (RBX)
Normalized name: ethanol
DrugBank: Ruboxistaurin (DB11829)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ruboxistaurin (RBX) 16 mg twice daily for 28 days
Study: 16384948
Drug: Ruboxistaurin (RBX)
Normalized name: ethanol
DrugBank: Ruboxistaurin (DB11829)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ruboxistaurin (RBX) (8 mg twice a day, 16 mg per day, or 16 mg twice a day)
Study: 14598034
Drug: German version
Normalized name: German cockroach allergenic extract
DrugBank: Blatella germanica (DB10418)
Approvals — FDA: no, EMA: no, PMDA: no
Description: German version of the Structured Inventory of Malingered Symptomatology (SIMS) administered to students instructed to feign conditions
Study: 14598034
Drug: German version
Normalized name: German cockroach allergenic extract
DrugBank: Blatella germanica (DB10418)
Approvals — FDA: no, EMA: no, PMDA: no
Description: German version of the Structured Inventory of Malingered Symptomatology (SIMS) administered to students responding honestly
Study: 14598034
Drug: German version
Normalized name: German cockroach allergenic extract
DrugBank: Blatella germanica (DB10418)
Approvals — FDA: no, EMA: no, PMDA: no
Description: German version of the Structured Inventory of Malingered Symptomatology (SIMS) administered to sexually delinquent patients with antisocial personality disorders
Study: 8629845
Drug: Oral tacrolimus
Normalized name: Tacrolimus
DrugBank: Tacrolimus (DB00864)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral tacrolimus (FK 506) at an initial dose of 0.05 mg/kg per day, increased to 0.10 and 0.15 mg/kg per day if necessary
Study: 8629845
Drug: Oral tacrolimus
Normalized name: Tacrolimus
DrugBank: Tacrolimus (DB00864)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral tacrolimus (FK 506)
Study: 1475268
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg flupirtine
Study: 1475268
Drug: 200 mg
Normalized name: RNA 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg flupirtine
Study: 20538704
Drug: Disease-modifying treatments
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Disease-modifying treatments (DMTs)
Study: 20538704
Drug: Symptomatic treatments
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Symptomatic treatments (STs)
Study: 18923170
Drug: Monovalent type
Normalized name: collagen type I
Approvals — FDA: no, EMA: no, PMDA: no
Description: Monovalent type 1 oral poliovirus vaccine
Study: 18923170
Drug: Trivalent oral
Normalized name: poliovirus vaccine, live, trivalent oral solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trivalent oral poliovirus vaccine
Study: 15892276
Drug: Erigeron injection
Normalized name: ERIGERON CANADENSIS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Erigeron injection (EI) 40 ml/d for 15 days
Study: 11936731
Drug: Vitamin A
Normalized name: Vitamin A
DrugBank: Vitamin A (DB00162)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin A supplements for 6 weeks
Study: 11936731
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no vitamin A supplements)
Study: 9894936
Drug: Comparison between
Approvals — FDA: no, EMA: no, PMDA: no
Description: Comparison between vaccine and control groups
Study: 2076677
Drug: 300 mg
Normalized name: rutin 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 300 mg chloroquine base weekly for six months
Study: 7191229
Drug: Glycopyrrolate, 0.0045
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glycopyrrolate, 0.0045 mg/kg IV
Study: 7191229
Drug: Glycopyrrolate, 0.008
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glycopyrrolate, 0.008 mg/kg IV
Study: 7191229
Drug: Atropine, 0.009
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atropine, 0.009 mg/kg IV
Study: 19142668
Drug: HA+FU infusion
Normalized name: fu ling
Approvals — FDA: no, EMA: no, PMDA: no
Description: HA+FU infusion group
Study: 9734727
Drug: Aspartame (high
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspartame (high dose: 45 mg x kg body wt(-1) x d(-1))
Study: 9734727
Drug: Aspartame (low
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspartame (low dose: 15 mg x kg body wt(-1) x d(-1))
Study: 7999480
Drug: Topical analgesia
Normalized name: ANALGESIC TOP GEL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical analgesia
Study: 31399381
Drug: Personalised mechanical
Normalized name: PIPERONYL BUTOXIDE TECHNICAL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Personalised mechanical ventilation (based on lung morphology); tidal volume of 8 mL/kg for focal ARDS, 6 mL/kg for non-focal ARDS, low PEEP, recruitment manoeuvres, and prone position.
Study: 31399381
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group received standard care; tidal volume of 6 mL/kg, low PEEP, and encouraged early prone position.
Study: 30095773
Drug: Individualized oxycodone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Individualized oxycodone prescription (predicted based on each patient's inpatient opioid use)
Study: 30095773
Drug: Standard oxycodone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard oxycodone prescription (30 tablets of 5 mg oxycodone)
Study: 30095773
Drug: Individualized oxycodone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Individualized oxycodone prescription
Study: 30095773
Drug: Standard oxycodone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard oxycodone prescription
Study: 27159341
Drug: Plasma varenicline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Plasma varenicline levels ≥3ng/mL
Study: 27159341
Drug: Plasma varenicline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Plasma varenicline levels ≥5ng/mL
Study: 20194013
Drug: Oxytocin 5-unit
Normalized name: oxytocin 5 UNT/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxytocin 5-unit bolus and placebo infusion
Study: 20194013
Drug: Oxytocin 5-unit
Normalized name: oxytocin 5 UNT/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxytocin 5-unit bolus and oxytocin 30-unit infusion
Study: 17638549
Drug: Oral diclofenac
Normalized name: diclofenac Oral Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral diclofenac sodium (50 mg for body weight <70 kg; 100 mg for body weight >70 kg) 60 minutes prior to SWL
Study: 17638549
Drug: Topical EMLA
Normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Topical EMLA (5 g) 60 minutes prior to SWL
Study: 17638549
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of oral diclofenac sodium and topical EMLA (5 g) 60 minutes prior to SWL
Study: 11061518
Drug: Standard recombinant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard recombinant human GH therapy (0.3 mg/kg x week)
Study: 11061518
Drug: High dose
Normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dose recombinant human GH therapy (0.7 mg/kg x week)
Study: 9279533
Drug: Glibenclamide 10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glibenclamide 10 mg
Study: 8336373
Drug: Drug treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug treatment (chlorthalidone, acebutolol, doxazosin mesylate, amlodipine maleate, enalapril maleate)
Study: 8336373
Drug: Drug treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug treatment (all drug groups combined)
Study: 3459351
Drug: Standard gemfibrozil
Normalized name: Gemfibrozil
DrugBank: Gemfibrozil (DB01241)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Standard gemfibrozil dosage of two 300-mg capsules 2 times a day (total 1200 mg daily)
Study: 3459351
Drug: 600-mg tablet
Normalized name: ubidecarenone 600 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 600-mg tablet of gemfibrozil 2 times a day (total 1200 mg daily)
Study: 3459351
Drug: Two 450-mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two 450-mg tablets of gemfibrozil once a day in the evening
Study: 2968669
Drug: Colchicine capsule
Normalized name: Colchicine Capsules
DrugBank: Colchicine (DB01394)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Colchicine capsule (burst dose regimen)
Study: 31064666
Drug: Liquid oral
Normalized name: M-End Liquid Oral Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Liquid oral nutritional supplement (ONS)
Study: 29101841
Drug: Educational Support
Approvals — FDA: no, EMA: no, PMDA: no
Description: Educational Support Therapy (C)
Study: 25933976
Drug: Zinc sulphate
Normalized name: Zinc sulphate
DrugBank: Zinc acetate (DB14487)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Zinc sulphate (220 mg containing 50mg zinc element) for 12 weeks
Study: 21284697
Drug: Nicotine Patch
Normalized name: Nicotine Patch
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nicotine Patch (Nicotinell Patch 10cm(2), 17.5mg nicotine, average delivery rate 7mg/24h)
Study: 19307503
Drug: Pemetrexed 500
Normalized name: pemetrexed 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pemetrexed 500 mg/m² (arm A)
Study: 19307503
Drug: Pemetrexed 500
Normalized name: pemetrexed 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pemetrexed 500 mg/m² plus carboplatin AUC 5 (arm B)
Study: 11134438
Drug: Oral iron
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral iron group (9 mg/kg/day of iron polymaltose complex)
Study: 11134438
Drug: EPO +
Normalized name: epoetin alfa
DrugBank: Erythropoietin (DB00016)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: EPO + oral iron group (300 U of recombinant human EPO kg/day and daily oral IPC)
Study: 11134438
Drug: Intravenous iron
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous iron + EPO group (2 mg/kg/day of intravenous iron sucrose, r‐HuEPO, and oral iron)
Study: 8381146
Drug: Vinblastine 5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vinblastine 5 minutes after BBL injection
Study: 8381146
Drug: Control lesions
Normalized name: scabies lesion lysate (human)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control lesions (BBL, saline, or no treatment)
Study: 19093004
Drug: All formulations
Normalized name: Novel Influenza-H1N1-09, all formulations
Approvals — FDA: no, EMA: no, PMDA: no
Description: All formulations (PfAMA1 with Alhydrogel, Montanide ISA720, AS02)
Study: 16966690
Drug: Belagenpumatucel-L (1.25,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Belagenpumatucel-L (1.25, 2.5, or 5.0 x 10(7) cells/injection) administered monthly or every other month for a maximum of 16 injections
Study: 14582545
Drug: Cannulated screws
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cannulated screws combined with calcium‐phosphate cement for augmentation
Study: 10699943
Drug: T+GLA (Gamma
Approvals — FDA: no, EMA: no, PMDA: no
Description: T+GLA (Gamma linolenic acid with tamoxifen 20 mg od)
Study: 10699943
Drug: Tamoxifen 20
Normalized name: tamoxifen 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tamoxifen 20 mg od alone
Study: 8411294
Drug: Standard auricular
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard auricular acupuncture treatment
Study: 8411294
Drug: Sham treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sham treatment (geographically close points)
Study: 31895658
Drug: Marine n-3
Normalized name: 22:6(n-3)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Marine n-3 fatty acids (1 g/d)
Study: 15784492
Drug: Intravenous supplementary
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous supplementary nutrition (1000 kcal/day for 3 days, followed by oral supplementary nutrition (400 kcal/day for 7 days))
Study: 11897546
Drug: 20% human
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20% human albumin 50 ml
Study: 7916403
Drug: Recombinant interleukin-2
Normalized name: Recombinant interleukin-2 human
DrugBank: Aldesleukin (DB00041)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Recombinant interleukin-2 (1 MU) with hepatitis B vaccine (20 micrograms)
Study: 7916403
Drug: Placebo with
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo with hepatitis B vaccine (20 micrograms)
Study: 31033364
Drug: Naproxen 220-750
Normalized name: naproxen 750 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Naproxen 220-750 mg/day
Study: 26722699
Drug: Oral health
Normalized name: CETYLPYRIDINIUM CHLORIDE 0.07 g in 100 mL ORAL RINSE [Assured Oral Health Fresh Mint]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral health training for care-staff
Study: 26722699
Drug: Scaled up
Normalized name: Q-Up
Approvals — FDA: no, EMA: no, PMDA: no
Description: Scaled up oral health training for all staff
Study: 7890075
Drug: Synchronized administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Synchronized administration of hCG at the onset of the endogenous LH rise (J group)
Study: 7890075
Drug: Non-synchronized administration
Normalized name: Tavist Non-Sedating
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-synchronized administration of hCG (non-J group)
Study: 1854108
Drug: Aminophylline (loading
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aminophylline (loading dose followed by routine infusion, n = 65)
Study: 1854108
Drug: Placebo (equal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (equal volume as loading dose and infusion, n = 68)
Study: 6661511
Drug: Medroxalol solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medroxalol solution (100 mg)
Study: 6661511
Drug: Medroxalol tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medroxalol tablet formulation (100 mg)
Study: 6661511
Drug: Medroxalol intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medroxalol intravenous (100 mg)
Study: 15037490
Drug: Light to
Normalized name: MINERAL OIL,LIGHT TOPICAL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Light to moderate alcohol consumption (monthly, weekly, daily)
Study: 15037490
Drug: Light to
Normalized name: MINERAL OIL,LIGHT TOPICAL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Light to moderate alcohol consumption (monthly, weekly, daily) among men with systolic BP ≥140 mm Hg or diastolic BP ≥90 mm Hg
Study: 11709512
Drug: Balsalazide 3.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Balsalazide 3.0 g twice daily
Study: 11709512
Drug: Balsalazide 1.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Balsalazide 1.5 g twice daily
Study: 11709512
Drug: Mesalazine 0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mesalazine 0.5 g three times daily
Study: 8561442
Drug: verapamil LI
Approvals — FDA: no, EMA: no, PMDA: no
Description: verapamil LI 120 mg 3 times a day
Study: 8561442
Drug: verapamil LP
Normalized name: LP-20
Approvals — FDA: no, EMA: no, PMDA: no
Description: verapamil LP 120 mg twice a day
Study: 2122015
Drug: Biosynthetic human
Normalized name: Proinsulin biosynthetic human
DrugBank: Proinsulin human (DB17875)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Biosynthetic human growth hormone (BSHGH) 0.1 mg/kg/day for 7 days
Study: 2122015
Drug: Biosynthetic human
Normalized name: Proinsulin biosynthetic human
DrugBank: Proinsulin human (DB17875)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Biosynthetic human growth hormone (BSHGH)
Study: 21834489
Drug: ezetimibe 10
Normalized name: ezetimibe 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: ezetimibe 10 mg + atorvastatin 10 mg
Study: 21834489
Drug: atorvastatin 20
Normalized name: atorvastatin 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: atorvastatin 20 mg + placebo
Study: 15729016
Drug: Cefaclor 50
Normalized name: cefaclor 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefaclor 50 mg/kg/day for 5 days
Study: 15729016
Drug: Cefaclor 40
Normalized name: Cefaclor
DrugBank: Cefaclor (DB00833)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cefaclor 40 mg/kg/day for 10 days
Study: 9210991
Drug: Pre-treatment depression
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pre-treatment depression
Study: 9210991
Drug: Interpersonal problems
Normalized name: isopropyl alcohol
DrugBank: Isopropyl alcohol (DB02325)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Interpersonal problems at pre-treatment
Study: 8353046
Drug: Low-dose recombinant
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose recombinant interleukin-2 (rIL-2) at dose levels of 0.18, 0.6, 1.8, or 6 x 10(6) IU m-2 24 h-1; one patient treated with 3 x 10(6) IU m-2 24 h-1
Study: 2297142
Drug: Active treatment
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active treatment with oral immunotherapy (Artemisia pollen extract) over a 50-day course, cumulative dose of 396,652 PNU
Study: 268377
Drug: 1 APF
Normalized name: Alprostadil
DrugBank: Alprostadil (DB00770)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 1 APF tablet containing 1 mg fluoride
Study: 268377
Drug: 2 APF
Normalized name: Alprazolam
DrugBank: Alprazolam (DB00404)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 2 APF tablets (3 hours apart) each school day
Study: 268377
Drug: 1 placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 placebo tablet
Study: 31554360
Drug: HDR brachytherapy
Normalized name: OCTOCRYLENE 5 g in 100 mL / OCTINOXATE 7.5 g in 100 mL / OCTISALATE 5 g in 100 mL / AVOBENZONE 3 g in 100 mL / HOMOSALATE 2 g in 100 mL TOPICAL CREAM [Mineralium Hdra Source Moisturizing Protector SPF 25]
Approvals — FDA: no, EMA: no, PMDA: no
Description: HDR brachytherapy with concurrent chemotherapy (Paclitaxel and Carboplatin)
Study: 24288948
Drug: Fish oil
Normalized name: Fish oil
DrugBank: Fish oil (DB13961)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fish oil (FO) supplementation (1 g/day for 3 months)